JPRN-UMIN000024162尚未招募未知
Comparison between intravesical BCG therapy and intravesical BCG and MMC therapy for prevention of recurence and treatment of in situ cancer in non-muscle invasive bladder cancer patients with intermediate or high risk disease. - Comparison between intravesical BCG and BCG+MMC therapy for prevention of recurence and treatment of in situ cancer in intermediate or high risk non-muscle invasive bladder cancer.
agasaki University Hospital0 个研究点目标入组 284 人开始时间: 2016年9月27日最近更新:
适应症
试验速览
- 阶段
- 未知
- 状态
- 尚未招募
- 发起方
- 入组人数
- 284
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 ot applicable（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •1: The chance of living over 6 months 2: With active tuberculosis 3: Allergy for BCG or MMC 4: With other maligancy or has plan of treatment for the disease. 5: The doctor judged as improper.
研究者
相似试验
已完成
3 期
A randomized study of intravesical BCG therapy for superficial bladder cancer -The comparative study for low doses of BCG treatmentSuperficial bladder cancer (Ta or T1, Grade1-2)JPRN-C000000364Kinki University School of Medicine160
已完成
不适用
Influences of intravesical BCG therapy in lower urinary tract symptomrothelial carcinoma in situ of the bladderJPRN-UMIN000040457Kinki Central Hospital of Mutual Aid Association of Public School Teachers40
招募中
不适用
Influences of intravesical BCG therapy in lower urinary tract symptomrothelial carcinoma in situ of the bladderJPRN-UMIN000040796Kinki Central Hospital of Mutual Aid Association of Public School Teachers40
进行中（未招募）
不适用
Intravesical instillation of BCG strain RIVM versus TICE for prevention of recurrenec in patients with high-risk papillary superficial carcinomas of the urinary bladder. A randomised phase II clinical trial - BCG RIVM vs. BCG TICE in patients with high-risk superficial bladder cancerEUCTR2005-001775-35-ATmedac GmbH186
暂停
不适用
A prospective comparative study of intravesical Bacillus Calmette-Guerin (BCG) therapy with the Tokyo or Connaught strains for non-muscle invasive bladder cancerBladder cancerJPRN-UMIN000009347Keiji Ogura200